Biomea Fusion Inc (BMEA)

In May 2026, Biomea Fusion announced poster presentations of icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions, leading to a stock price increase. In April 2026, the company announced positive 52-week results from its Phase 2 COVALENT-112 trial in Type 1 diabetes, but the stock experienced a decline. In March 2026, Biomea Fusion announced the first patient dosed in newly initiated Phase II programs enrolling Type 2 diabetes patients, resulting in a stock increase, and reported its full-year 2025 financial results. In February 2026, the stock saw an increase. In January 2026, the stock increased. An FDA clinical hold on COVALENT-111 and -112 trials was resolved in late 2024/early 2025, shifting the company's focus to clinical acceleration.

As a clinical-stage biopharmaceutical company, Biomea Fusion currently has no commercial revenue and therefore no discernible demand seasonality. The company's customer base, including patients with Type 2 Diabetes and select cancers, specialist clinicians, and institutional payers, will become relevant for demand once products are commercialized.

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing covalent small molecule drugs for genetically defined cancers and metabolic diseases like diabetes and obesity. The company utilizes its proprietary FUSION System discovery platform to advance its pipeline, with lead product candidate icovamenib being investigated for Type 1 and Type 2 diabetes and obesity, promoting beta-cell proliferation and improved function. Their second product candidate, BMF-650, is an investigational oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of diabetes and obesity.

Biomea Fusion's primary geographical market presence is in the United States, accounting for approximately 45% of its strategic focus, with headquarters in San Carlos, California. Clinical operations have expanded into the EU, including Germany, France, and Spain, to access diverse patient populations and meet EMA requirements. International expansion into the EU and Asia-Pacific accelerated in 2025 to capture diverse patient registries and growth in metabolic disease prevalence. China and India are prioritized for the diabetes portfolio due to the high prevalence of diabetes in these regions.

Biomea Fusion's brand reputation has been shaped by clinical trial results and analyst coverage, with encouraging clinical data for icovamenib and BMF-650 leading to generally positive analyst ratings. The average analyst rating is "Moderate Buy" with a 12-month target price of $8.29. An FDA clinical hold in May 2024 interrupted trials but was later resolved. Despite positive clinical data announcements, the stock has sometimes experienced negative price reactions.

Biomea Fusion's ownership is primarily held by institutional investors, accounting for 48.17% of shares as of August 2025, with major holders including Fmr Llc, Heights Capital Management, Inc., and Cormorant Asset Management, LP. Insider ownership, representing shares held by directors and executives, accounts for 28.91% of the company, with notable individual shareholders including co-founder Thomas Butler and co-founder Rainer M. Erdtmann. Retail investors make up the remaining 22.92% of Biomea Fusion's ownership.